$ASRT 1.08 a bullish rating on it's equity summary score. PENDING NEWS. This is a great time to get in on this one.
Assertio Therapeutics Announces Sale of Gralise® for Total Transaction Value of $127.5 Million GlobeNewswire GlobeNewswire•December 12, 2019 LAKE FOREST, Ill., Dec. 12, 2019 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (“Assertio”) (ASRT), today announced it has entered into an agreement with Alvogen, a global privately held pharmaceutical company, under which Alvogen will acquire and assume all responsibilities associated with the product Gralise® (gabapentin). The agreement is expected to close in early January 2020, subject to regulatory approval.
Under the terms of the agreement, Alvogen will pay Assertio a total value of $127.5 million. This includes $75 million in cash upon closing and the balance payable in the form of a royalty on the first $70 million in Gralise® net sales. Both companies expect the majority of the royalties to be paid in the first calendar year.
News 
Market Data 
Discover 
